Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

BACKGROUND: TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monother...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Gastroenterol
Main Authors: Sugiura, Kiyoaki, Seo, Yuki, Takahashi, Takayuki, Tokura, Hideyuki, Ito, Yasuhiro, Tanaka, Motomu, Kishida, Norihiro, Nishi, Yusuke, Onishi, Yoshihiko, Aoki, Hikaru
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058969/
https://ncbi.nlm.nih.gov/pubmed/33879100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-021-01771-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados